| Title |
A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil
|
|---|---|
| Published in |
Patient preference and adherence, August 2015
|
| DOI | 10.2147/ppa.s56002 |
| Pubmed ID | |
| Authors |
Jeffery D Evans, Stephen R Hill |
| Abstract |
Numerous pathways can lead to erectile dysfunction (ED) in patients, with some patients having multiple causes. Regardless of the etiology, ED has been successfully treated in many patients with the advent of oral phosphodiesterase-5 inhibitors (PDE5Is). With the release of avanafil, there are currently four PDE5I options available, and choosing between them should be based on patient-specific considerations and preferences. To review the treatment of ED with PDE5Is, taking into account the effectiveness, safety, and patient satisfaction of these agents, as well as avanafil's place in therapy. A PubMed search was completed to find articles published in English studying patient satisfaction and adherence to ED medication. Additional searches looked specifically for any data regarding the use of avanafil. ED is effectively treated in most patients with PDE5Is, with the most common side effects from the medications being headache, flushing, and visual disturbances. Patients have identified many different factors, such as efficacy, side effects, duration of action, and daily use, in determining overall satisfaction and the right medication for them. While avanafil does not have any patient satisfaction trials to date, it has been proven to be a safe and effective treatment for ED with possibly the fastest onset of action and fewer visual disturbances than its competitors. Avanafil along with the other PDE5Is has shown to be a safe and effective oral treatment for ED, with avanafil's possible place in therapy for patients who want an on-demand option or as an alternative in patients who experience visual disturbances with the other agents. |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 47 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 21% |
| Researcher | 7 | 15% |
| Student > Bachelor | 7 | 15% |
| Student > Doctoral Student | 4 | 9% |
| Other | 3 | 6% |
| Other | 5 | 11% |
| Unknown | 11 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 13% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Nursing and Health Professions | 3 | 6% |
| Agricultural and Biological Sciences | 3 | 6% |
| Other | 5 | 11% |
| Unknown | 14 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 December 2021.
All research outputs
#2,111,244
of 25,576,275 outputs
Outputs from Patient preference and adherence
#85
of 1,769 outputs
Outputs of similar age
#26,336
of 276,796 outputs
Outputs of similar age from Patient preference and adherence
#4
of 54 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,769 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,796 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.